Marinomed Biotech AG
Marinomed Biotech AG Reports Financial Results for 1st Quarter 2021: Growth in Sales, due to persistent strong demand in Carragelose-based virus blockers
DGAP-News: Marinomed Biotech AG
/ Key word(s): Quarter Results
Marinomed Biotech AG Reports Financial Results for 1st Quarter 2021: Growth in Sales, due to persistent strong demand in Carragelose-based virus blockers Conference call to be held today, 26 May 2021; 10:00 am CEST / 9:00 am BST
Korneuburg, Austria, 26 May 2021 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today reported strong growth for the first quarter of 2021. Marinomed’s revenues more than doubled to € 2.2 m (Q1 2020: € 1.0 m). The increase mainly resulted from the continued demand in the Company’s Carragelose-based virus blockers, especially in comparison to the pre-pandemic Q1 2020. Clinical data published in early 2021 confirmed Marinomed’s previous findings that Carragelose virus blocker is effective against SARS-CoV-2, reinforcing the demand for Carragelose-based products during the pandemic. Due to increased research & development (R&D) investments in the two technology platforms, Marinosolv and Carragelose, the operating result (EBIT) decreased to € -1.7 m (Q1 2020: € -1.4 m), which is in-line with Marinomed’s business plan. Marinomed confirms its previously forecast financial outlook for the full fiscal year 2021. “Our first quarter results are characterized by continued strong demand for Carragelose-based products, which provide a sensible addition to the existing pandemic prevention and treatment armory. On the scientific side, we saw exciting progress: A multicenter Argentinian trial demonstrated that Carragelose’s antiviral mode of action is able to combat SARS-CoV-2. This is, at least in vitro, also true for several Corona variants, which we showed together with researchers in Germany during the first quarter this year,” said Dr. Andreas Grassauer, Marinomed’s CEO. “In parallel, we are achieving relevant progress with our Marinosolv platform. Besides Carragelose, Marinosolv is an important cornerstone in our future strategy. The Marinosolv technology is broadly applicable to a range of drug formulations, significantly improving solubility, bioavailability and efficacy in comparison to conventional medicines. With our current development programs in allergic, ophthalmologic, and gastrointestinal indications, we hope to provide improved drug formulations to patients in the future.” Operative highlights in Q1 2021 and after the reporting period:
Q1 Financial Results Persistent strong demand for Carragelose-based virus blockers propelled Marinomed’s revenues in the first quarter. Revenues increased by almost 119 % compared to Q1 2020 (Q1 2020: € 1.0 m), mainly driven by Carragelose product sales. The increasing demand triggered by the pandemic more than compensated the general decline in common cold and flu products – in some markets the pharmaceutical industry faced a drop of over 50 % in revenues for this segment (Source: IQVIA). As planned, Marinomed intensified its efforts in R&D during Q1 2021. Expenses amounted to € 2.2 m compared to € 0.9 m in the same quarter in 2020, an increase of 151 %. The R&D efforts covered both research platforms, Carragelose and Marinosolv, with Carragelose capturing approximately 65 % of total external R&D investments. Marinomed’s strong focus on Carragelose is a response to the COVID-19 pandemic. In the future, Marinomed intends, as already announced, to re-shift the focus in R&D activities to the Marinosolv platform, in which the Company sees large future potential. The growth of R&D investments resulted in an increased operating loss (EBIT) of € 1.72 m in Q1 2021, up from € 1.41 m (Q1 2020). Net loss for the period was € 2.10 m compared to € 1.57 m in Q1 2020. The higher net loss reflects a small increase in financing expenses to € 0.35 m from € 0.17 m in the previous period. Operating and net loss are in line with the Company’s business plan and outlook as stated in the annual report 2020. Marinomed confirms its financial outlook for the fiscal year: The Company expects Carragelose sales to grow further but below the 2020 level. Marinomed plans a slight increase in R&D costs leading to an operating loss in fiscal 2021. Select financial figures for Q1 2021
The full quarterly statement can be found on the Company’s website: https://www.marinomed.com/en/investors/publications Conference Call Details: Marinomed Biotech AG (VSE:MARI) will talk about these first quarter financial results in an international conference call (held in English language), today. The conference call is scheduled for 10.00 a.m. CET (9.00 a.m. GMT). Your conference call partners will be Dr. Andreas Grassauer, CEO, and Pascal Schmidt, CFO. Participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call: The presentation can be downloaded approx. 15 minutes before the conference call from the Company’s website: https://www.marinomed.com/en/investors/publications About Marinomed Biotech AG For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.
26.05.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |